A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results.
4130^ Introduction: Pmab is a fully human antibody targeting the epidermal growth factor receptor that is approved as monotherapy for mCRC in the US, EU, and Canada. AMG 655 is an investigational, fully human agonistic antibody against death receptor 5. This is the first study to evaluate the safety...
| Publicado en: | Journal of Clinical Oncology Vol. 27; pp. 4130 - 4131 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
5/21/2009 Supplement Part 1 of 2
|
| Acceso en línea: | Ver este registro en EBSCOhost |